2019冠狀病毒疾病（Coronavirus disease 2019, COVID-19）自2019年底起開始快速肆虐全球，這種疾病是由急性嚴重呼吸症候群冠狀病毒2（severe acute respiratory syndrome coronavirus-2, SARS-CoV2）引起，主要造成肺部急性且快速廣泛侵犯及損傷，進而造成缺氧與呼吸衰竭。然而除了肺部的影響之外，COVID-19會引起的全身系統性影響。儘管肝臟非COVID-19感染的主要侵犯器官，但研究發現COVID-19常合併有肝生化檢驗異常，且與COVID-19感染嚴重度有關，可做為重症COVID-19的預後因子之一。目前對於COVID-19引起的肝受損機轉，除了肝臟組織細胞被病毒感染侵犯，還可能透過全身性發炎反應、全身性缺氧、凝血功能異常、內皮功能缺損、醫源性因素（例如藥物給予）影響肝臟機能。台灣是一個慢性肝病流行地區，COVID-19感染對於肝臟直接傷害與慢性肝病的衝擊，導致的肝臟受損與病程長期的效應，在慢性肝炎病患不容忽視。COVID-19感染於慢性肝病的病患治療，除抗病毒藥物治療與支持療法，還需注意抗新冠病毒藥物與慢性肝病的抗病毒藥物的交互作用。本文對於COVID-19及慢性肝病的處置也進一步探討跟描述。

In these 3 years, coronavirus disease 2019 (COVID-19) has spread throughout the world. Although the primary infection sites of COVID-19 infection are airway and lung, plenty of case series had showed there was various organs involvement. As for hepato-biliary system, accumulative studies have revealed abnormal liver functions were frequently found in patient with COVID-19. Besides, those abnormalities were more in patient with severe COVID-19. This finding suggested that abnormal liver function might be one of the poor prognostic factors. The hepatic injury in patient with COVID-19 might be caused by direct virus invasion, systemic inflammatory reaction, systemic hypoxia, abnormal coagulation, injured endothelium, and iatrogenic cause. Taiwan is a chronic liver disease endemic area, and the impact of hepatic injury of COVID-19 should not be ignored. In this article, we also describe the correlation between abnormal liver function and the severity of COVID-19. The mechanism of hepatic injury and the management of chronic liver disease in patient with COVID-19 are also mentioned.